Understanding the treatment of attention deficit hyperactivity disorder in newly diagnosed adult patients in general practice: a UK database study

被引:10
作者
Bushe, Christopher [1 ]
Wilson, Bernard [2 ]
Televantou, Foula [1 ]
Belger, Mark [1 ]
Watson, Louise [3 ]
机构
[1] Lilly UK, Erl Wood Manor, Windlesham GU20 6PH, Surrey, England
[2] Lilly UK, Basingstoke, Hants, England
[3] EpiPharmaCo Ltd, Buxton, Derby, England
来源
PRAGMATIC AND OBSERVATIONAL RESEARCH | 2015年 / 6卷
关键词
adult ADHD; prescribing; health care; health outcomes; epidemiology; CPRD;
D O I
10.2147/POR.S74161
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Adult attention deficit hyperactivity disorder (ADHD) has been largely ignored in psychiatric and general practice guidance until recently. Adult ADHD has a high social and medical burden, but health care is not well described in the UK. The main study objective was to evaluate a primary care adult ADHD population in terms of prescribing and health care contact rates. Methods: This was a retrospective observational study using data from the Clinical Practice Research Database from January 1, 2002 to July 31, 2011. Adult patients with an incident ADHD diagnosis or ADHD medication were identified as having been free of ADHD medication or diagnoses in the previous 2 years. Patients were followed for 12-24 months after diagnosis. Results: Of the 663 patients with ADHD in the cohort, 54.1% were prescribed ADHD medication during the observation period. During the first 6 months, 34.2% of patients initiated methylphenidates and 14.0% atomoxetine. In total, 36.3% patients were referred to secondary care psychiatry during observation, with the remaining population (63.7%) never having a referral. Most of the referrals were before diagnosis in primary care. At the end of the observation period, 16.2% of patients were on antipsychotics, 17.3% hypnotics, and 34.8% antidepressants or anxiolytics; however, some patients appeared to be prescribed antipsychotic or antidepressant medications even if they did not have an observable diagnosis in their records. Health care contact rates (general practitioner or hospital) increased by 39.2% post-diagnosis (incidence rate ratio: 1.39; 95% confidence interval: 1.32, 1.47), which may be related to the need for medication monitoring and titration. Conclusion: This study has shown in primary care that there is relatively low use of ADHD medication, low referrals into secondary care, high rates of usage of psychiatric non-ADHD medications for different indications, and an increasing burden in terms of health care contacts in adult ADHD patients post-diagnosis.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 28 条
  • [1] Once-Daily Atomoxetine for Adult Attention-Deficit/Hyperactivity Disorder A 6-Month, Double-Blind Trial
    Adler, Lenard A.
    Spencer, Thomas
    Brown, Thomas E.
    Holdnack, James
    Saylor, Keith
    Schuh, Kory
    Trzepacz, Paula T.
    Williams, David W.
    Kelsey, Douglas
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2009, 29 (01) : 44 - 50
  • [2] American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, DOI 10.1176/appi.books.9780890425596
  • [3] American Psychiatric Association, 2000, DIAGN STAT MAN MENT, DOI DOI 10.1016/B978-1-4377-2242-0.00016-X
  • [4] Under Diagnosis of Adult ADHD: Cultural Influences and Societal Burden
    Asherson, Philip
    Akehurst, Ron
    Kooij, J. J. Sandra
    Huss, Michael
    Beusterien, Kathleen
    Sasane, Rahul
    Gholizadeh, Shadi
    Hodgkins, Paul
    [J]. JOURNAL OF ATTENTION DISORDERS, 2012, 16 (05) : 20S - 38S
  • [5] Mortality, ADHD, and Psychosocial Adversity in Adults With Childhood ADHD: A Prospective Study
    Barbaresi, William J.
    Colligan, Robert C.
    Weaver, Amy L.
    Voigt, Robert G.
    Killian, Jill M.
    Katusic, Slavica K.
    [J]. PEDIATRICS, 2013, 131 (04) : 637 - 644
  • [6] Unrecognized Attention-Deficit/Hyperactivity Disorder in Adults Presenting with Other Psychiatric Disorders
    Barkley, Russell A.
    Brown, Thomas E.
    [J]. CNS SPECTRUMS, 2008, 13 (11) : 977 - +
  • [7] Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology
    Bolea-Alamanac, Blanca
    Nutt, David J.
    Adamou, Marios
    Asherson, Phillip
    Bazire, Stephen
    Coghill, David
    Heal, David
    Mueller, Ulrich
    Nash, John
    Santosh, Paramala
    Sayal, Kapil
    Sonuga-Barke, Edmund J. S.
    Young, Susan J.
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2014, 28 (03) : 179 - 203
  • [8] Bushe Chris J, 2012, J Clin Psychiatry, V73, pe749, DOI 10.4088/JCP.11m07246
  • [9] A review of hyperprolactinaemia and severe mental illness: Are there implications for clinical biochemistry?
    Bushe, Chris J.
    Bradley, Andrew
    Pendlebury, John
    [J]. ANNALS OF CLINICAL BIOCHEMISTRY, 2010, 47 : 292 - 300
  • [10] Serious Transport Accidents in Adults With Attention-Deficit/Hyperactivity Disorder and the Effect of Medication A Population-Based Study
    Chang, Zheng
    Lichtenstein, Paul
    D'Onofrio, Brian M.
    Sjolander, Arvid
    Larsson, Henrik
    [J]. JAMA PSYCHIATRY, 2014, 71 (03) : 319 - 325